Login to Your Account



Blockbuster Potential?

Inflammagen's Shok-Pak Taking on Septic Stock in Phase II Trial

By Catherine Shaffer
Staff Writer

Monday, March 12, 2012

If early human trial results from Inflammagen Therapeutics Inc. are borne out in its new Phase II pilot study, disclosed Monday, the company could have a major blockbuster on its hands, according to CEO John Rodenrys.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription